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AbstrACt
Introduction Women presenting with suspected 
pre-eclampsia are currently triaged on the basis of 
hypertension and dipstick proteinuria. This may result in 
significant false positive and negative diagnoses resulting 
in increased morbidity or unnecessary intervention. Recent 
data suggest that placental growth factor testing may be 
a useful adjunct in the management of women presenting 
with preterm pre-eclampsia. The primary objective of this 
trial is to determine if the addition of placental growth 
factor testing to the current clinical assessment of women 
with suspected preterm pre-eclampsia, is beneficial for 
both mothers and babies.
Methods and analysis This is a multicentre, stepped 
wedge cluster, randomised trial aiming to recruit 4000 
women presenting with symptoms suggestive of 
preterm pre-eclampsia between 20 and 36+6 weeks’ 
gestation. The intervention of an unblinded point of care 
test, performed at enrolment, will quantify maternal 
levels of circulating plasma placental growth factor. The 
intervention will be rolled out sequentially, based on 
randomisation, in the seven largest maternity units on the 
island of Ireland. Primary outcome is a composite outcome 
of maternal morbidity (derived from the modified fullPIERS 
model). To ensure we are not reducing maternal morbidity 
at the expense of earlier delivery and worse neonatal 
outcomes, we have established a co-primary outcome 
which will examine the effect of the intervention on 
neonatal morbidity, assessed using a composite neonatal 
score. Secondary analyses will examine further clinical 
outcomes (such as mode of delivery, antenatal detection 
of growth restriction and use of antihypertensive agents) 
as well as a health economic analysis, of incorporation of 
placental growth factor testing into routine care.
Ethics and dissemination Ethical approval has been 
granted from each of the seven maternity hospitals 
involved in the trial. The results of the trial will be 
presented both nationally and internationally at conference 
and published in an international peer-reviewed journal.
trial registration number NCT02881073.
bACkground   
Pre-eclampsia is characterised by hyperten-
sion and proteinuria, complicates 2%–8% 
of pregnancies, and is associated with signif-
icant maternal and neonatal morbidity and 
mortality.1 Currently, women who present 
with suspected pre-eclampsia are triaged on 
the basis of hypertension and dipstick protein-
uria. Both of these clinical end points are 
subject to observer error and poor test accu-
racy, with false positive and negative diagnoses 
of pre-eclampsia occurring in clinical prac-
tice.2–5 Current biochemical tests are imper-
fect at stratifying women for more intensive 
surveillance as they only identify advanced 
disease where there is already marked 
end-organ damage.6 While biomarkers and 
imaging techniques have been evaluated 
for improving detection, none has adequate 
sensitivity and/or specificity for the diagnosis 
of pre-eclampsia.7 
Placental growth factor (PlGF) belongs 
to the vascular endothelial growth factor 
(VEGF) family and represents a key regulator 
strengths and limitations of this study
 ► Randomised trial.
 ► Multiple sites with wide geographic distribution.
 ► Stepped wedge design.
 ► Placental growth factor testing only in the interven-
tion arm.
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of angiogenic events in pathological conditions.8 PlGF 
exerts its biological function through the binding and 
activation of the receptor Flt-1.9 10 In pre-eclampsia, 
it is thought that endothelial dysfunction leads to an 
increased level of a circulating decoy receptor, known as 
soluble Flt-1, (sFlt-1), a soluble receptor for both vascular 
endothelial growth factor type A (VEGF-A) and PlGF.11 
Circulating levels of sFlt-1 are increased in pre-eclampsia 
and particularly in the early onset form of the disease, 
resulting in reduced levels of free VEGF-A and PlGF in the 
maternal circulation. Thus, the endothelial dysfunction 
observed in pre-eclampsia may be due to excess neutrali-
sation of VEGF-A and PlGF by circulating sFlt-1. Levine et 
al showed that in normal pregnancy, PlGF levels track the 
development of the placenta, peaking at about 32 weeks’ 
gestation when the placenta is developed fully and then 
declining until delivery.12 However, in pre-eclampsia, this 
rise and fall is considerably lower throughout pregnancy, 
and levels are strikingly lower when the condition pres-
ents clinically.
The PELICAN study (Plasma Placental Growth Factor 
in the Diagnosis of Women with Pre-Eclampsia Requiring 
Delivery Within 14 Days:) was the first and largest 
prospective evaluation of PlGF in women presenting 
with suspected pre-eclampsia.13 This blinded observa-
tional cohort study was conducted in seven consultant-led 
maternity units in the UK and Ireland between January 
2011 and February 2012. It enrolled women being inves-
tigated for suspected pre-eclampsia, quantified their 
plasma PlGF using a point of care device, the Alere Triage 
PlGF test, but did not reveal the result to their clini-
cian. The study found that a PlGF value <100 pg/mL, in 
women presenting prior to 35 completed weeks’ gesta-
tion had a negative predictive value of 98% (95% CI 93 to 
99.5) and a positive predictive value of 44% (95% CI 36 
to 52) in determining those that would require delivery 
for a confirmed diagnosis of pre-eclampsia within the 
next 14 days. The study reported a PlGF <100 pg/mL to 
be a better predictor than all other current commonly 
used predictive tests of pre-eclampsia, either singly or in 
combination (blood pressure, urinalysis or biochemical 
markers) with an area under the receiver operating char-
acteristic curve for low PlGF of 0.87 compared with 0.76 
for the next best predictor.
The PROGNOSIS study (Predictive value of the sFlt-
1:PlGF ratio in women with suspected preeclampsia) was 
a prospective, multicentre, blinded, observational study 
conducted in 14 countries from 2011 to 2014.14 Its aim 
was to derive and validate a ratio of serum sFlt-1 to PlGF 
that would be predictive of the absence or presence of 
pre-eclampsia in the short term. It included women with 
singleton pregnancies from 24 weeks to 36+6 weeks’ 
gestation in whom a clinical suspicion of pre-eclampsia 
existed. The Elecsys immunoassay was used to quan-
tify levels of PlGF and sFlt-1. The development cohort 
of over 500 participants identified a sFlt-1:PlGF ratio of 
38 as having an important predictive value. The subse-
quent validation cohort, again with over 500 participants, 
reported a negative predictive value of 99.3% (95% CI 
97.9 to 99.9) for ruling out pre-eclampsia within 1 week. 
Interestingly, the same cut-off of 38 was predictive of the 
absence of fetal adverse outcomes within 1 week; nega-
tive predictive value of 99.3% (95% CI 97.9 to 99.9). 
The study showed that an sFlt-1:PlGF ratio of 38 or lower 
can be used to predict the short-term absence of pre-ec-
lampsia and adverse fetal events in women in whom the 
syndrome is suspected clinically.15 The positive predic-
tive value, a diagnosis of pre-eclampsia, eclampsia or the 
HELLP syndrome (haemolysis, elevated liver enzymes 
and a low platelet count) within 4 weeks, was 36.7% 
(95% CI 28.4 to 45.7) using the same sFlt-1:PlGF ratio 
of 38. Post hoc analysis however showed this was still an 
improvement in prediction compared with the use of 
clinical variables such as blood pressure and urinalysis 
alone.
The National Institute for Health and Clinical Excel-
lence, UK (NICE) has recently published guidance on 
incorporation of PlGF testing, in addition to clinical 
assessment, in women presenting with suspected pre-ec-
lampsia from 20 to 34+6 weeks’ gestation. It advises that 
the Triage PlGF test or Elecsys immunoassay sFlt-1/
PlGF ratio test may be used, in combination with clinical 
assessment, to ‘rule-out’ pre-eclampsia in this group of 
women. However, it advises that these tests should not yet 
be used to diagnose pre-eclampsia until further research 
is available, specifically on how an abnormal PlGF result 
would affect management decisions regarding timing 
and gestation of delivery and the outcomes associated 
with this.16
The objective of this randomised trial is to evaluate the 
impact of knowledge of PlGF measurement on clinically 
relevant outcomes. We hypothesise that adding PlGF 
measurement to current clinical assessment of women 
with suspected pre-eclampsia prior to 37 weeks' gesta-
tion will reduce associated maternal morbidity through 
improved risk stratification, earlier diagnosis and targeted 
management of women with the disease. Any interven-
tion in late pregnancy may have an impact on the fetus. 
On the one hand, earlier diagnosis of pre-eclampsia may 
precipitate earlier delivery and lead to an increase in 
neonatal morbidity and mortality secondary to iatrogenic 
prematurity. Conversely, improved identification of those 
neonates at highest risk of imminent placental dysfunc-
tion may reduce neonatal morbidity by allowing for timely 
intervention. It is therefore imperative that full evalu-
ation of both potential benefit and harm is conducted 
before PlGF testing is implemented routinely into clinical 
practice. If this trial demonstrates a beneficial impact on 
maternal morbidity and/or neonatal morbidity, along-
side a favourable health economic assessment, then there 
would be a strong case for incorporating PlGF testing into 
routine clinical investigations for women presenting with 
suspected pre-eclampsia before 37 weeks’ gestation in a 
wide variety of healthcare settings.
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MEthods And dEsIgn
study design
PARROT Ireland is a multicentre, stepped wedge clus-
ter-controlled trial of PlGF measurement in women 
presenting with suspected pre-eclampsia from 20 weeks 
and prior to 37 weeks' gestation. As implementation 
of a diagnostic test may alter physician management, a 
cluster design was chosen rather than individual rando-
misation. This allows for a change in management to 
occur at a hospital rather than at an individual woman 
level, which is preferable in trials involving a diagnostic 
test and allows the clinical influence of the additional test 
to be evaluated in a pragmatic fashion.17 Each maternity 
hospital acts as a cluster. All clusters commenced the trial 
in the control arm and in turn, each cluster transitions at 
random from the control to the intervention at prespec-
ified time points. Once a cluster has changed over to the 
intervention, it continues as such for the remainder of 
the trial so that by the end of the trial all clusters will be in 
the intervention arm (figure 1). A stepped wedge design 
was chosen so as to increase the social acceptability of the 
trial to the seven hospitals (the stake holders/decision 
makers in all of the hospitals expressed a desire to partic-
ipate in a trial in which they were guaranteed to get the 
intervention); and because a trial with just seven clusters 
risks baseline imbalance in a parallel design.
The trial will continue for a period of 22 months, 
and with seven clusters the interval between transitions 
is approximately 3 months in duration. A restricted 
method of randomisation was used to provide a balance 
in total (expected) number of observations across inter-
vention and control periods (details below).18–20 There 
is a short transition period of 1 week whenever a new 
cluster transitions from control to the intervention. 
Data collected during this transition period will not be 
included in any analysis of outcomes. Recruitment will 
stop on a prespecified fixed date in late April 2019 and 
the study will end when the last recruited participant and 
neonate are discharged and all outcome data collected.
setting and participants
The trial is being conducted within the Health Research 
Board Mother and Baby Clinical Trial Network Collab-
orative. The Coombe Women and Infants University 
Hospital Dublin, Cork University Maternity Hospital, 
University Maternity Hospital Limerick, The Royal Jubilee 
Maternity Hospital Belfast, University College Hospital 
Galway, The National Maternity Hospital Dublin and The 
Rotunda Maternity Hospital Dublin are the seven largest 
consultant-led maternity units on the island of Ireland. 
Combined, they have an annual birth rate of over 44 000, 
representing over half of the country’s total annual births. 
Women attending these maternity units who present with 
suspected preterm pre-eclampsia are eligible for inclu-
sion in this trial. Detailed inclusion and exclusion criteria 
are described in boxes 1 and 2.
randomisation
The trial statisticians for the study developed a rando-
misation sequence for site transition from control to 
intervention; however, the order of site transitioning is 
concealed from sites and principal investigators until 
12 weeks prior to the sites transition date. An allocation 
sequence was randomly selected (ie, a cross-over order 
for the seven clusters) from a set of random sequences 
constrained so that the sum of the total cluster sizes in 
Figure 1 Stepped wedge cluster randomised design for PARROT Ireland.
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the intervention status was similar to the total sum of the 
cluster sizes in the control status. Similar was defined to 
be a difference in the total sums exposed to intervention 
and control statuses being no different than the expected 
middle 25th percentile range of differences. To imple-
ment this, 10 000 simulations of possible (unique) alloca-
tion sequences were performed. From this, the difference 
in number exposed to intervention and control for each 
sequence was determined. An allocation sequence was 
then selected at random from those falling within the 
middle 25th percentile range of differences.17–19
Control
Eligible women are approached and provided with 
detailed information about the trial, both verbally and 
written, by a trained researcher. Eligibility is determined 
by review of symptoms and signs at the time of presen-
tation to the maternity hospital by the local researcher. 
Participants are not aware of their maternity hospitals 
current randomisation prior to their enrolment on the 
trial. Informed consent is obtained in accordance with 
ICH—GCP guidelines.21 Once an eligible woman has 
given written informed consent for inclusion in the 
study, her maternity hospitals current group alloca-
tion is revealed (figure 2). Participants enrolled in the 
control arm receive usual hospital care as per National 
guidelines; these are Health Service Executive/Insti-
tute of Obstetrics and Gynaecology Irish guidelines for 
those in the Republic or the NICE guidelines for those in 
Northern Ireland (figure 3A,B).22 23 Eligible women who 
are approached but who decline to participate in the trial 
will continue to receive usual hospital care.
Intervention
Participants enrolled in the intervention arm have their 
plasma PlGF quantified in addition to routine hospital 
investigations. The PlGF result is made immediately 
available to the participants clinical team and docu-
mented clearly in the participant’s medical notes. A 
suggested further management algorithm is provided 
to the clinician based on both the degree of hyper-
tension present and the PlGF result (figure 4). This 
algorithm advocates increased frequency of review for 
those participants identified as having an abnormal 
PlGF result. The final decision regarding frequency of 
review remains with the treating clinician. If 4 weeks or 
more pass and the participant represents with symp-
toms suggestive of pre-eclampsia, a repeat PlGF quan-
tification may be performed as long as the inclusion/
exclusion criteria are still satisfied. In certain sites the 
option of plasma Biobanking will be available. Partic-
ipants will be consented separately for this. For those 
who give consent, a portion of the specimen taken will 
be used to measure the level of PlGF in the plasma and 
the remainder of the sample will be stored in University 
College Cork Biobanking facility.
PlgF quantification
Maternal plasma PlGF quantification is performed on 
an EDTA venous blood sample obtained in the standard 
fashion. Plasma is obtained through centrifugation and 
the sample is then processed immediately using a CE 
marked validated point of care platform; the automated 
Triage Meterpro (ALERE San Diego, California, USA). 
Each hospital has the necessary equipment in situ and 
appropriately trained researchers in place, to perform 
this test as per manufacturer’s guidelines. The PlGF 
measurement is reported as the absolute value in pg/mL 
within 30 min of commencing processing of the sample. 
All samples taken will be analysed without delay by the 
researcher after venepuncture has occurred and in accor-
dance with manufacturer's instructions. The Triage PlGF 
test platform and consumables necessary to perform 
testing are brought to the cluster just at the point of tran-
sition to intervention. It is therefore not available at site 
for use while the site is in the control arm.
box 1 Inclusion criteria
Pregnant women between 20+0 and 36+6 weeks of gestation (inclu-
sive) with a;
 ► Singleton pregnancy.
 ► Aged 18 years or over.
 ► Able to give informed consent.
 ► Presenting with suspected pre-eclampsia: (one or more of the 
following):
 – Hypertension;
 – Dipstick proteinuria;
 – Headache;
 – Visual disturbances;
 – Epigastric or right upper quadrant pain;
 – Increasing oedema;
 – Suspected fetal growth restriction;
 – If the healthcare provider deems that the woman requires further 
evaluation for possible pre-eclampsia.
box 2 Exclusion criteria
 ► Confirmed pre-eclampsia at point of enrolment: ‘sustained hy-
pertension with systolic blood pressure (BP)≥140 or diastolic 
BP≥90 mm Hg on at least two occasions (at least 4 hours apart) with 
significant quantified proteinuria (>300 mg protein on 24 hours col-
lection or urine protein creatinine ratio>30 mg/mmol) or abnormal 
pre-eclampsia bloods’.
 ► ≥37 weeks' gestation.
 ► Multiple pregnancy.
 ► Abnormal pre-eclampsia bloods (new-onset reduced number of 
platelets or deranged liver function/renal function tests, identified 
during routine care prior to enrolment and not attributable to any-
thing other than pre-eclampsia).
 ► Decision regarding imminent delivery already made.
 ► Lethal fetal abnormality present.
 ► Previous participation in PELICAN trial in a prior pregnancy.
 ► Participation in a conflicting trial at the same time as PARROT 
Ireland.
 ► Plan to use off protocol placental growth factor testing.
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Patient and public involvement
Patients/public were not involved in the development of 
this trial.
outcome measure
Primary outcome measure
To evaluate if the intervention is beneficial to both 
women and their babies and more importantly to 
ensure it is not harmful to either, the study has two 
equally important co-primary outcome measures. These 
are maternal morbidity and neonatal morbidity. For 
maternal morbidity assessment, an adaption of the full-
PIERS score is used (box 3). The definition of hepatic 
dysfunction is based on alanine aminotransferase rather 
than International Normalised Ratio (INR), require-
ment for intensive care unit admission is included as well 
as the presence of severe hypertension. Severe systolic 
hypertension is an independent risk factor for stroke in 
pregnancy and in high-resource settings uncontrolled 
hypertension is the main cause of death in women with 
pre-eclampsia.24–26 The interval from diagnosis of pre-ec-
lampsia to delivery is not a suitable outcome measure to 
use, as we are aware that knowledge of PlGF result may 
alter clinician management and expedite delivery.27 For 
neonatal morbidity assessment, babies are dichotomised 
into having or not having identified neonatal morbidity 
by means of a composite neonatal score (box 4). In 
order to avoid subjectivity in the diagnosis of morbidity, 
the majority of components of the neonatal composite 
score are objective measures; pH<7.2, positive cultures, 
admission to NICU. We acknowledge that some subjec-
tivity can arise with staging of disease hence why all stages 
of each disease will be captured and will comprise the 
composite outcome; NEC stage 1–3, IVH grade 1–4 and 
ROP stage 1–5. Neonatal outcomes and morbidity will be 
captured from local case note review, as documented by 
the treating neonatologist. In cases where any uncertainty 
is present, the researcher will discuss the case with the 
local Principal Investigator (PI) and or the trial clinical 
fellow and a consensus will be reached
Secondary outcome measure
Secondary outcomes include each component of the 
primary outcome reported individually as well as further 
maternal and neonatal assessments such as mode of 
delivery and use of antihypertensive agents (boxes 5 
and 6). Fetal growth restriction, identified on antenatal 
ultrasound, has been included as a secondary outcome 
measure of neonatal morbidity. As PlGF correlates well 
with placental dysfunction, it may be able to differentiate 
between those babies with pathological growth restriction 
rather than constitutional growth restriction and hence 
improve neonatal outcomes.
A separate health economic evaluation is assessing 
the intervention’s economic impact. This is achieved 
through the use of participant quality of life (QoL) 
questionnaires (EuroQol 5D and Short-Form 36),28 29 a 
specially designed study-specific participant costing ques-
tionnaire and by assessment of costs to the health service 
Figure 2 Trial schematic for PARROT Ireland. HTN, hypertension; NICE, National Institute for Health and Clinical Excellence; 
PlGF, placental growth factor.
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of community-based/inpatient/day case care, through 
chart review at discharge.30–32
Data collection
Trial data captured locally at site by researchers are trans-
mitted securely using an electronic clinical record form 
(eCRF) to a specific database developed by MedSciNet. 
Baseline demographic data, QoL questionnaires and 
the PlGF result are entered live to the eCRF at point of 
recruitment. The full eCRF is completed after discharge 
from the maternity hospital postdelivery, and includes 
neonatal and maternal medical outcome, costing 
questionnaire and repeat QoL questionnaires. All data 
entered to the eCRF is pseudo-anonymised with each 
participant identified by a unique study number. The 
identifier key is kept separately locally at site in a secure 
location. The data system is built to the same security and 
confidentiality standards as those of hospital electronic 
health records. The data at each participating centre are 
handled in accordance with local regulatory legislation 
and ethics committee approval. A detailed description 
of schedule and timing of data collection is provided in 
table 1.
Figure 3 (A) Management algorithm for control arm based on Health Service Executive (HSE) guidelines for PARROT Ireland. 
(B) Management algorithm for control arm based on NICE guidelines for PARROT Ireland. AFI, amniotic fluid index; BP, blood 
pressure; CTG, cardiotocography; NICE, National Institute for Health and Clinical Excellence; US, ultrasound.
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sample size
The sample size was fixed by the number of sites and 
the study duration. It is anticipated that the total sample 
size will be in the region of 4000 participants; split across 
seven clusters and the eight time periods in the design 
(equivalent to a cluster-period size of about 71). With a 
sample size of 4000 and using a two-sided type I error rate 
of 0.025 (to allow for two co-primary outcomes), we deter-
mined the power to detect a 7% reduction in maternal 
morbidity (relative risk reduction of 20%) from 35% to 
28% in the intervention, that is, ‘active’ group (based 
on a reported rate of adverse maternal outcome in the 
region of 35% in the PELICAN trial).13 33 This is assuming 
an intraclass correlation (ICC) in the region of 0.01; and 
consider sensitivity to a range of intracluster correlation 
(ICC) values between 0.005 and 0.05. The second co-pri-
mary outcome is adverse neonatal outcomes. Due to scar-
city of information on the ICC, the same ICC as for the 
maternal outcome is assumed. Current rates of adverse 
events are around 10%. We determine power to detect 
an absolute change in neonatal adverse outcomes of 6%.
To allow for the longitudinal nature of the trial, where 
correlations may differ between observations in the same 
Figure 4 Suggested management algorithm for intervention for PARROT Ireland. BP, blood pressure; CTG, cardiotocography; 
PlGF, placental growth factor; US, ultrasound.
box 3 Components of the maternal morbidity composite 
score
 ► Confirmed placental abruption.
 ► Intensive care admission.
 ► Central nervous system compromise:
 – Generalised tonic clonic seizure due to eclampsia, Glasgow 
Coma Scale (GCS)<13, cerebral haemorrhage/infarct, cortical 
blindness, retinal detachment, transient ischaemic attack, re-
versible ischaemic neurological deficit.
 ► Cardiorespiratory compromise:
 – Myocardial ischaemia/infarction, SpO2<90%,  >50% 
FiO2for  >1 hour, intubation (other than for caesarean section), 
pulmonary oedema, need for positive inotrope support.
 ► Haematological compromise:
 – Transfusion of any blood product, platelet count<100×109/L.
 ► Liver compromise:
 – Hepatic dysfunction (alanine aminotransferase or aspartate ami-
notransferase>70 IU/L, haematoma, rupture.
 ► Kidney compromise:
 – Acute renal insufficiency (creatinine>150 μmol/L); haemodialysis.
 ► Severe hypertension:
 – Systolic blood pressure≥160 mm Hg on at least one occasion.
box 4 Components of the neonatal morbidity composite 
score
 ► Perinatal death or death before hospital discharge.
 ► Neonatal intensive care unit admission for ≥48 hours.
 ► Birth weight ≤5th customised centile*.
 ► Apgar score<7 at 5 min.
 ► Umbilical artery acidosis at birth (cord pH<7.2).
 ► Admission to neonatal unit.
 ► Respiratory distress syndrome.
 ► Interventricular haemorrhage (IVH).
 ► Retinopathy of prematurity (ROP).
 ► Confirmed infection (confirmed on blood or cerebrospinal fluid 
cultures).
 ► Necrotising enterocolitis (NEC).
*Customised birth weight at delivery is calculated using the Gestation Related 
Optimal Weight (GROW) centile.
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cluster-period; and those measured in different cluster 
periods, we incorporate cluster-autocorrelations (CAC). 
There is little information to support likely values for 
the CAC, so we are guided by values in the literature and 
explore sensitivity across a range of values (0.64, 0.80 and 
0.96).34 35
The power has been estimated using an online RShiny 
App.36 37 We have not included transition periods in 
the calculation but given the transition periods are just 
1 week in length, this is not expected to significantly affect 
power. There has been no allowance for varying cluster 
sizes as this is currently not something which is technically 
possible in a stepped wedge study. Sample size calcula-
tions were performed assuming linear mixed models with 
categorical effects for time; random cluster and random 
cluster by period effects.38 Under these assumptions, we 
constructed power curves, which reveal that under most 
anticipated scenarios the trial will have in the region of 
80% power (figures 5 and 6).35 39
data analysis
Clinical outcome
The primary aim of the study is to evaluate whether there 
is a difference in the two composite outcomes before 
and after exposure to the intervention. There will be no 
double counting of outcomes, individuals not events will 
be presented for the composite. Mixed effects regression 
models will be used to allow for the clustering within sites. 
Calendar time will also be adjusted for since the interven-
tion is sequentially rolled-out both by including fixed cate-
gorical time effects and random cluster by categorical time 
effects.40
The primary estimate of the treatment effects will there-
fore be cluster and time adjusted. Time adjustment is 
essential, as it is a stepped wedge trial. Log Poisson regres-
sion models with robust variance estimation (to allow for 
misspecification of binomial errors) will be used so as to 
allow estimates of relative risks41; to estimate risk differences 
corresponding Binomial models with log links will be fitted. 
Secondary analysis will adjust for individual and cluster 
level covariates. In the first instance, comparative estimates 
of differences between groups will be adjusted for variables 
used in the randomisation procedure (eg, site, time and 
hospital size). Furthermore, more fully adjusted analyses 
will also be performed. These more fully adjusted analyses 
will adjust for gestational age at recruitment, maternal age, 
smoking status, maternal body mass index, public versus 
private obstetric care and maternal comorbidities such as 
chronic renal disease, systemic lupus erythematosus (SLE), 
antiphospholidip syndrome (APS) and diabetes. It will 
also adjust for hospital size (<5000 or >5000 deliveries/
annum). Categorised continuous variables (eg, age) will 
be treated as continuous variables in this adjustment. If 
covariate adjustment is not practical, unadjusted estimates 
will be produced and it will be made clear in the output 
why this occurred (eg, not possible due to low event rate 
lack of model convergence). Null hypotheses and analyses 
for secondary outcomes take a similar form to that for the 
primary outcome, and where outcomes are not binary, 
analysis will be using the generalised linear mixed model. 
box 5 secondary outcomes—maternal
 ► Final diagnosis of hypertensive disorder of pregnancy (chronic hy-
pertension (HTN), gestational HTN or pre-eclampsia).
 ► Gestation at diagnosis of pre-eclampsia.
 ► Use of one or more antihypertensive drugs.
 ► Instrumental delivery (ventouse or forceps):
 ► Severe HTN (systolic blood pressure (BP) ≥160 mm Hg on at least 
one occasion);
 ► Maternal morbidity by fullPIERS model;
 – Confirmed placental abruption;
 – Intensive care admission;
 – Central nervous system compromise;
 – Cardiorespiratory compromise;
 – Haematological compromise;
 – Liver compromise;
 – Kidney compromise.
 ► Progression to severe pre-eclampsia as defined by the  American 
College of Obstetricians and Gynecologists practice bulletin:
 – Systolic BP≥160 mm Hg or diastolic BP≥110 mm Hg on two oc-
casions at least 4 hours apart while the patient is on bed rest 
(unless antihypertensive therapy is initiated before this time);
 – Thrombocytopenia (platelet count<100×109/L);
 – Impaired liver function as indicated by abnormally elevated blood 
concentrations of liver enzymes (to twice normal concentration), 
severe persistent right upper quadrant or epigastric pain unre-
sponsive to medication and not accounted for by an alternative 
diagnoses, or both;
 – Progressive renal insufficiency (serum creatinine concentration 
>1.1 mg/dL (150 μmol/L) or a doubling of the serum creatinine 
concentration in the absence of other renal disease);
 – Pulmonary oedema;
 – New-onset cerebral or visual disturbances.
 ► Elective delivery: induction of labour or caesarean section.
 ► Caesarean section: emergency and elective
box 6 secondary outcomes—neonatal
 ► Fetal growth restriction identified on antenatal ultrasound* (estimat-
ed fetal weight and/or abdominal circumference <10th customised 
centile, abnormality in umbilical artery Doppler velocity or reduced 
level of amniotic fluid).
 ► Gestation at delivery.
 ► Perinatal death or death before hospital discharge.
 ► Admission to neonatal intensive care unit (NICU).
 ► NICU admission for ≥ 48 hours.
 ► Birth weight ≤ 5th customised centile.
 ► Apgar score < 7 at 5 min.
 ► Umbilical artery acidosis at birth (arterial cord pH<7.2).
 ► Respiratory distress syndrome.
 ► Interventricular haemorrhage.
 ► Retinopathy of prematurity.
 ► Confirmed infection (confirmed on blood or cerebrospinal fluid 
cultures).
 ► Necrotising enterocolitis.
*Antenatal detection of fetal growth restriction is based on formal ultrasound 
assessment of fetal biometry using the Hadlock formula.
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Transformations will be performed where data are mark-
edly not normally distributed. For the analysis adjusted for 
covariates and for the secondary outcomes (unadjusted), 
multiple imputation methods will be used if the proportion 
of missing data is >5%, and this multiple imputation will 
also allow for the clustered and temporal nature of the trial. 
It is not expected that there will be any missing data in the 
primary outcome, as it will be assumed that if the outcome 
is present then it will be recorded and if it is not recorded 
we will assume it is absent. This is a standard and realistic 
assumption. Results will be presented as adjusted risk ratios 
with CIs and risk differences to allow full appreciation of 
clinical effect. To allow for the two primary outcomes, we 
will follow good practice and adjust for this multiplicity 
using a Bonferroni correction and so report 97.5% CIs.
For secondary continuous outcomes mean differences 
will be reported and 99% CIs for secondary outcomes. We 
will report latent ICCs for all outcomes, along with 95% CIs. 
Prespecified subgroup analysis will be undertaken on the 
primary outcome based on women presenting <35 weeks' 
gestation vs >35 weeks' gestation; size of unit and final 
confirmed diagnosis. The stepped wedge trial design will 
also allow investigation of treatment effect heterogeneity 
across clusters and time. These exploratory analyses will 
be reported using 99% CIs. Analysis will be conducted by 
intention to treat and sites will be considered exposed to 
the intervention postrandomised cross-over date.
Health economic outcome
The economic evaluation will be informed by a decision 
analytical model, which will be designed and constructed 
for the study to reflect the maternal and fetal pathway and 
health states. Employing a decision analytical model allows 
for the extrapolation of existing data and the opportunity 
Table 1 Standard Protocol Items: Recommendations for Interventional Trials flow diagram for schedule of events in PARROT 
Ireland
On presentation with suspected PET
Between 20+0 and 36+6 weeks
From enrolment to 
discharge postdelivery
Discharge 
postdelivery
In-person visit Chart In-person visit Chart
In-person 
completed
Randomisation-institutional level X
Inclusion/exclusion X
Informed consent X
Demographics X*
History, comorbidities X*
Con medications X* X
Physical measurements X*
Clinical readings X*
PlGF† measurement X X‡
Biobank sample§ X
Fetal assessments X
Prenatal admissions X
Maternal PET bloods X
Newborn data X
Neonatal outcome X
Maternal outcome X
Complications X
Postnatal admissions X
Clinical management X
Final outcomes X
EQ-5D, SF-36 X X
Costing questionnaire X
In-person visits X X‡
*May be captured in chart review or in consultation with participant at any time following enrolment.
†PlGF testing depends on institutional randomisation allocation.
‡PlGF testing will be repeated if readmission for suspected pre-eclampsia. May be repeated more than once. No more often than four weekly.
§Only at biobanking sites.
EQ-5D, EuroQol 5D; PlGF, placental growth factor; SF-36, Short-Form 36.
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to systematically synthesise evidence from various sources. 
Primary data on maternal health outcomes will be available 
from the study with the distribution of 5-level EQ-5D version 
and SF-36 questionnaires which will inform the estimation 
of quality-adjusted life years (QALYs). Neonatal outcomes 
will be informed by secondary sources. A systematic litera-
ture review will be conducted to identify QOL/utilities (or 
proxies for same) associated with neonate outcomes, which 
will be incorporated into the decision analytical model to 
estimate QALYs. Primary data on resource utilisation will 
be collected using the costing questionnaire. The costs and 
effects of the intervention and comparator will be compared 
with an incremental cost-effectiveness ratio in a cost utility 
analysis. To address parameter and structural uncertainties, 
a probabilistic sensitivity analysis will be performed.
trial management
Day-to-day running of the trial will be coordinated by the 
Trial Management Group (TMG). The TMG consist of 
the lead site investigator plus the project manager and 
the clinical fellow. The TMG will act on behalf of the 
sponsor and will be responsible to the Trial Steering 
Figure 5 Power curve for PARROT Ireland for maternal adverse outcomes. CAC, cluster-autocorrelation; ICC, intracluster 
correlation.
Figure 6 Power curve for PARROT Ireland for neonatal adverse outcomes. CAC, cluster-autocorrelation; ICC, intracluster 
correlation.
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Committee (TSC) to ensure that all sponsors’ responsi-
bilities are carried out. The TSC comprises all PIs as well 
as the TMG, sponsor, Health Research Board (HRB) and 
representatives from statistics, economics, neonatology, 
laboratory and a lay person. The role of the TSC is to 
provide overall supervision of the trial. In particular, the 
TSC will concentrate on the progress of the trial, adher-
ence to the protocol, participant safety and consideration 
of new information.
data monitoring
To provide protection for study participants an inde-
pendent data monitoring committee (DMC) has been 
appointed for this trial. The DMC comprises four 
members who are not involved with any other aspect of 
the trial. They include an obstetrician, a neonatologist, 
a statistician and a midwife. The DMC met and ratified 
their charter and have advised that all serious adverse 
events such as stillbirth/neonatal death or profound 
maternal morbidity in the Intervention arm of the study 
be reported to them immediately. The DMC will receive 
regular updates on the progress of the trial every quarter 
from the TMG. The purpose of these updates is for the 
DMC to: 1) ensure the quality of data collection; 2) ensure 
that the intervention is being rolled out according to the 
randomisation plan; 3) monitor balance between arms to 
monitor for potential selection biases and 4) ensure PlGF 
testing is not overwhelmingly better or worse than no PlGF 
testing with respect to maternal morbidity with neonatal 
morbidity. Once 1500 outcomes are available an interim 
analysis will be conducted and reviewed by the DMC. The 
interim analysis will report on the co-primary outcomes, 
follow the same methods as those of the primary analysis 
and examine if there is proof beyond reasonable doubt 
that one particular intervention is definitely indicated 
or definitely contraindicated in terms of a net difference 
of a major end point. There will be no formal stopping 
criteria put in place, but the DMC will be guided by the 
knowledge that proof beyond reasonable doubt cannot 
be specified precisely, but a difference of at least three SD 
in an interim analysis of the primary outcome would be 
consistent with strong level of evidence. No allowance for 
this interim analysis has been made in power calculations.
There will be no stopping of the trial for futility as the 
study will be underpowered to detect small effects.
dIsCussIon
Based on previous experience during the PELICAN study, 
an analysis of success criteria and barriers to our proposed 
study was conducted. Potential barriers include the over-
estimation of (i) identification of eligible women by the 
research team, (ii) primary outcome event rate (iii) and 
retention/attrition, that is, gaining outcomes data on all 
women included.
A recruitment feasibility audit conducted in Cork 
University Maternity Hospital (CUMH) over the course 
of a typical week in July 2016 identified 21 women who 
would be eligible for inclusion in the PARROT Ireland 
study. This would equate to almost 1100 women per 
annum in CUMH, approximately 13% of its annual 
delivery rate. This is in keeping with the quoted 10% 
incidence of hypertensive disorders of pregnancy in the 
population.42 It is anticipated that over the 22-month 
duration of the study across the 7 hospitals approximately 
10 486 women will meet the study inclusion criteria (13% 
of the combined annual delivery rate), and of these 4000 
will be recruited into this trial (approximately 38% of 
those eligible). As inclusion in the trial will be optional 
and require informed consent from participants, not all 
eligible women in each unit will be included. Projected 
inclusion rates will be apparent via a dedicated MedSciNet 
database pre-programmed, available online and contem-
poraneously updated, allowing prompt action to inter-
vene when not optimal. A conservative requirement 
of <50% of all eligible women to be recruited in order to 
reach targets has deliberately been chosen and successful 
recruitment of the same population in the PELICAN 
study is reassuring. As with any study we may get a higher 
or lower incidence of the primary outcome of interest 
than anticipated. We should get an early indication of this 
at the interim analysis.
As participation in the trial does not require any 
extra attendances/input from the participant for the 
remainder of the pregnancy, it is likely that retention 
of participants will not be an issue. Similarly, the data 
outcome to assess for maternal and neonatal morbidity 
can be readily obtained postdelivery following discharge 
of the participant from their stored medical records 
locally at each unit. However, in order to fully examine 
the health economic outcomes there exists a reliance on 
the return of completed questionnaires by the participant 
postdelivery. To minimise attrition rates, the researcher 
at each site will endeavour to meet with each partici-
pant postdelivery prior to their discharge and encourage 
them to complete the health economic questionnaires. 
In the PELICAN study, only 1% of the cohort were lost 
to follow-up. The risk of incomplete data collection of 
outcomes in studies such as this is more relevant if women 
deliver in a different unit to that which they are recruited 
into the trial. However, all seven clusters in our trial are 
large tertiary referral units and patient transfer during 
pregnancy is rare. We are therefore confident that the 
likely rate of loss to follow-up will be similar and in the 
order of 1%.
There are a number of advantages with the use of 
stepped wedge design. It allows a phased implementation 
of the intervention, which is preferable when commence-
ment in all clusters simultaneously would be challenging. 
As all clusters ultimately receive the intervention, it 
increases willingness of the clusters to partake in the trial. 
We acknowledge that seven clusters is a small number of 
clusters and this is an important limitation of the study. 
Mostly, this is a limitation because it will mean that the 
findings have questionable generalisability. But, if these 
clusters are representative then the findings may still be 
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generalisable in part. The other limitation that seven 
clusters brings about is questionable internal reliability. 
However, because all of the clusters receive both the inter-
vention and control condition, the clusters serve as their 
own controls. This lessens the impact of chance imbal-
ance and it increases the power of the study (particularly 
so when the ICC is large, as is the case here). The study 
does only have in the region of 80% power and should 
parameters such as the ICC be very different to that which 
we have assumed, then it is correct that the study might be 
underpowered. To ensure that this is properly accounted 
for at the analysis stage, we will report appropriate CIs 
around all point estimates, so the impact of any impres-
sion is properly reported.
Another potential limitation worth noting is the slightly 
different management algorithm for one cluster, Belfast, 
in the control arm. The Belfast control arm algorithm is 
taken directly from the NICE Hypertension in Pregnancy 
guidelines. All other clusters are using an algorithm taken 
from the HSE guidelines for Hypertension in Pregnancy. 
The two are essentially the same except the HSE algorithm 
also includes a recommendation for a fetal ultrasound in 
cases where the participant is <34 weeks' gestation. It is 
not anticipated that the difference in these algorithms 
should have any bearing on the overall trial results. We 
will conduct a sensitivity analysis with the Belfast site 
removed and see if the result remains consistent.
Ideally, PlGF testing should be performed for all partic-
ipants enrolled in the study, with blinding of the result for 
those in the control arm. This would allow for test perfor-
mance statistics to be performed. Unfortunately, testing 
of control participants will not be conducted in our trial, 
which is a notable limitation of the study.
The primary aim of the PARROT Ireland trial is to estab-
lish the effectiveness of revealed plasma PlGF measure-
ment in reducing maternal morbidity (with assessment 
of neonatal safety in parallel) in women presenting with 
suspected pre-eclampsia prior to 37 weeks' gestation. 
Should the trial show a reduction in maternal morbidity 
without an increase in neonatal morbidity, or indeed 
a reduction in neonatal morbidity with no change in 
maternal morbidity, it would provide a strong argument 
for its incorporation into routine obstetric practice. 
The long-term aim of the trial is to demonstrate if PlGF 
measurement enables appropriate antenatal stratification 
of women presenting with suspected pre-eclampsia.
Avoiding unnecessary hospital admission would be both 
clinically and economically beneficial. In contrast, those at 
increased risk of imminent adverse events, identified by an 
abnormal PlGF result, would have hospital resources redi-
rected to them. We anticipate that this trial will provide a 
definitive result on the benefits of PlGF testing, which will 
act to influence international clinical practice.
A separate randomised controlled trial (RCT), also 
entitled ‘PARROT’, has completed recruitment in the UK 
since the end of 2017. Although recruiting a similar popu-
lation of women and using the same PlGF platform, the 
primary outcome measure for the two RCTs is different, 
with the UK PARROT trial focusing on time from enrol-
ment to diagnosis. Both studies are using the same elec-
tronic clinical record forms developed by MedSciNet and 
thus will have a large cross-over of data. The advantage of 
having these two similar RCTs conducted almost simulta-
neously is that robust information on the impact of incor-
poration of PlGF into clinical care will be generated. In 
addition, the potential exists for a collaborative project 
such as an individual participant data meta-analyses in the 
future.
dEClArAtIons
Ethics approval and consent to participate
The trial is being conducted in accordance with ethical 
principles that have their origin in the Declaration of 
Helsinki and are consistent with Good Clinical Prac-
tice (GCP) and applicable regulatory requirements. 
The local ethics committee at each participating site has 
reviewed the trial protocol, including the patient infor-
mation and informed consent form, and full ethical 
approval granted. Each eligible woman identified is 
required to give written informed consent prior to her 
inclusion in the trial. A GCP trained researcher at the 
local site obtains this consent.
Clinical Research Ethics Committee Cork: ECM 3 (h) 
08/11/16.
University College Hospital Galway EC: Ref 50/12.
Coombe Womens & Infants University Hospital EC: Study 
No 20–2016.
National Maternity Hospital EC: EC 20.2016.
University Hospital Limerick EC: Ref: 68/16.
Health Research Authority (Belfast): 16/WM/0484.
Rotunda Hospital EC: REC-2016–020.
dissemination
The success of the trial will be dependent entirely on the 
collaboration of clinicians in the participating hospitals 
and those who hold key responsibility for the trial. Hence, 
the credit for the study will be assigned to the key collabo-
rator(s) from a participating site as it is crucial that those 
taking credit for the work have actually carried it out. The 
results of the trial will be reported first to trial collabora-
tors. The results from the PARROT Ireland trial will be 
published in an established peer-reviewed journal. At least 
one publication of the main results will be made. Links to 
the publication will be provided in all applicable trial regis-
ters. Dissemination of results to participants will take place 
via the media, trial website and relevant participant organ-
isations. Collaborating investigators will play a vital role in 
disseminating the results to colleagues and participants.
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